About Cdymax (India) Pharma Private Limited
Data last updated:
Cdymax (India) Pharma Private Limited is a private limited company based in Bangalore, Karnataka, India, a subsidiary of M/S. Couplet Limited. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 27 October 1994 and has been in existence for over 32 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U85110KA1994PTC016472. Its GSTIN is 29AAACI8027N1Z4 (Karnataka).
The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹8.88 Cr. It was formerly known as Intermed Labs Private Limited. It is led by directors Santosh Datta Naik and Manorama Avinash.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 116/117 KIADB Indl Areajigani 2nd Phase Bangalore, Karnataka, India – 560105.
As per the financials filed for FY 2025, the company reported a revenue of ₹284.85 Cr, a growth of 12% compared to the previous year. For the same year it recorded a net profit of ₹7.3 Cr (net margin 2.6%) and EBITDA of ₹27.38 Cr (EBITDA margin 9.6%). Revenue has declined at a compounded annual rate (CAGR) of 6% over three years and 1% over five years.
The company has about 493 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Cdymax. As per MCA filings, the company has open charges of ₹82.98 Cr and satisfied charges of ₹66.47 Cr on record. Court records list 11 cases involving the company, including 4 filed by the company and 7 filed against it; 3 cases are pending. The company has 10 deals on record (6 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹66.48 Cr; the latest was in February 2020. Its 8 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Ajinomoto Bio-Pharma Services India Private Limited with revenue of ₹301.41 Cr. The company has 29 MSME Form 1 returns on record between 2018 and 2024, listing 1,058 overdue payments to 24 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website cdymax.in.
Company details
Name history
Cdymax (India) Pharma has undergone 3 name changes throughout its history. The company was previously known as Cdymax (India) Pharma Private Limited, Intermed Labs Private Limited, and Acebright (India) Pharma Private Limited. The current legal name is Cdymax (India) Pharma Private Limited.
| Company Name | Status |
|---|---|
| Cdymax (India) Pharma Private Limited | Current |
| Intermed Labs Private Limited | Previous |
| Acebright (India) Pharma Private Limited | Previous |
CIN history
Cdymax (India) Pharma has one previous CIN (Corporate Identification Number): U24231KA1994PTC016472. The current CIN is U85110KA1994PTC016472, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U85110KA1994PTC016472 | Current |
| U24231KA1994PTC016472 | Previous |
Contact details
Cdymax (India) Pharma Private Limited's registered office is in Bangalore, Karnataka. Its website is cdymax.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address116/117 KIADB Indl Areajigani 2nd Phase Bangalore, Karnataka, India – 560105
- IndustryPharma, API Manufacturers
To see the full contact details of Cdymax (India) Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Cdymax (India) Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Cdymax (India) Pharma Private Limited, buy the company report.
Financials of Cdymax (India) Pharma Private Limited
FY 2025 filings availableCdymax (India) Pharma Private Limited reported revenue of ₹284.85 Cr (up 12% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue rose 12% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 1%. EBITDA rose 181% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹27.38 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹7.3 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 9.6% | ||||
| Net Profit Margin | 2.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Cdymax (India) Pharma Private Limited, buy the company report.
Board of directors of Cdymax (India) Pharma Private Limited
Cdymax (India) Pharma has 2 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Santosh Datta Naik | Director | 08 Jan 2024 | 2 Years 9 Months | Current |
| Manorama Avinash | Director | 07 May 2011 | 15 Years 5 Months | Current |
Peer comparison
Cdymax (India) Pharma Private Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Ajinomoto Bio-Pharma Services India Private Limited | ₹301.41 Cr (FY 2025) | 56.0% | Anakapalle, Andhra Pradesh, India | |||
| Alembic Limited | ₹296.78 Cr (FY 2025) | 40.0% | Vadodara, Gujarat, India | |||
| Anjan Drug Private Limited | ₹293.42 Cr (FY 2025) | -14.0% | Chengalpattu Dt, Tamil Nadu, India | |||
| Arene Life Sciences (Unit 3) Private Limited | ₹287.8 Cr (FY 2025) | 53.0% | Hyderabad, Telangana, India | |||
| Cdymax (India) Pharma Private Limitedthis company | ₹284.85 Cr (FY 2025) | ₹7.3 Cr | 2.6% | 12.0% | 493 | Bangalore, Karnataka, India |
| Vijayasri Organics Private Limited | ₹280.5 Cr (FY 2025) | 16.0% | Hyderabad, Telangana, India | |||
| Jagson Pal Pharmaceuticals Limited. | ₹276.91 Cr (FY 2025) | 27.0% | New Delhi, Delhi, India | |||
| Embio Limited | ₹274.76 Cr (FY 2025) | 49.0% | Mumbai, Maharashtra, India | |||
| Sodium Metal Pvt Ltd | ₹273.32 Cr (FY 2023) | -11.0% | Vadodara, Gujarat, India |
To see the full peer comparison of Cdymax (India) Pharma Private Limited, buy the company report.
Auditor
Cdymax (India) Pharma Private Limited is audited by PATIL KABBUR & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| PATIL KABBUR & ASSOCIATES | FY 2023 | 015281S |
Shareholding
The shareholding of Cdymax (India) Pharma Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Cdymax (India) Pharma Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 20 May 2025 | 101106111 | Others | ₹20 Cr | Open | |
| 30 Nov 2021 | 100514100 | Others | ₹5.99 Cr | Open | |
| 20 Aug 2020 | 100367265 | Hdfc Bank Limited | ₹45 Cr | Open | |
| 03 May 2018 | 100181986 | Others | ₹60 Lakh | Open | |
| 03 May 2018 | 100181988 | Others | ₹60 Lakh | Open |
To see the full charge records of Cdymax (India) Pharma Private Limited, buy the company report.
Total charge records: 17 View all charges
Deals & funding
Cdymax (India) Pharma Private Limited has 10 deals on record (6 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹66.48 Cr; the latest was in February 2020.
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2013 | Secondary share transfer | Undisclosed | Buyer: Couplet Limited Seller: Medsyn Laboratories Private Limited |
| Aug 2011 | Secondary share transfer | Undisclosed | Buyer: Couplet Limited Seller: Medsyn Laboratories Private Limited |
| Sep 2010 | Secondary share transfer | Undisclosed | Buyer: Medsyn Laboratories Private Limited Seller: Med'lab Specialist Private Limited |
| Jun 2010 | Secondary share transfer | Undisclosed | Buyer: Couplet Limited Seller: Medsyn Laboratories Private Limited |
| Mar 2010 | Secondary share transfer | Undisclosed | Buyer: Couplet Limited Seller: Medsyn Laboratories Private Limited , Medsyn Therapeutics Private Limited |
To see the full deal history of Cdymax (India) Pharma Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Cdymax (India) Pharma Private Limited has 11 court cases on record: 4 filed by Cdymax (India) Pharma, 7 filed against it. 3 cases are pending and 8 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 7 | 5 | 3 |
| District courts | 4 | 2 | 0 |
Cases on record (5 of 11)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Karnataka | Court case (MFA) | Filed against the company by M/S United India Insurance Company Limited | Pending |
| High Court of Karnataka | Appeal | Filed against the company by GMP Technical Solutions Private Limited | Disposed |
| High Court, CHANDIGARH (UT) | Company petition | Filed by the company against M/S Health Biotech Limited | Disposed |
| High Court of Delhi | Commercial suit | Filed against the company by an individual | Pending |
| High Court of Delhi | Commercial suit | Filed against the company by Novartis Ag & Anr. | Pending |
To see the full case history of Cdymax (India) Pharma Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Cdymax (India) Pharma Private Limited was last rated by Care on 31 Mar 2023.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 31 Mar 2023 |
To see the full credit ratings and regulatory alerts of Cdymax (India) Pharma Private Limited, buy the company report.
MSME payment delays
Cdymax (India) Pharma Private Limited has 29 MSME Form 1 returns on record between 2018 and 2024, listing 1,058 overdue payments to 24 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 24)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Ascent Total Solution Private Limited | |||
| an individual supplier | |||
| Janani Water Technologies Private Limited | |||
| Advanced Calibration & Validation Services Private Limited |
To see the full MSME payment records of Cdymax (India) Pharma Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Cdymax (India) Pharma Private Limited has a workforce of 493 employees on its EPFO records as of Apr 09, 2024, across 2 active EPFO establishments.
GST
Cdymax (India) Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAACI8027N1Z4 | Karnataka | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Cdymax (India) Pharma Private Limited, buy the company report.
Recent activity
Cdymax (India) Pharma Private Limited has 9 board changes on record since 2009: 2 appointments and 7 cessations. The latest: Santosh Datta Naik ceased to be Additional Director on 29 Sep 2024.
23 earlier events are in the company report.
Frequently asked questions
Cdymax (India) Pharma is an active private limited company based in Bangalore, Karnataka, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 27 October 1994 (32+ years old) and is registered under CIN U85110KA1994PTC016472.
Cdymax (India) Pharma has 2 current directors:
- Santosh Datta Naik - Director
- Manorama Avinash - Director
The latest financial statements of Cdymax (India) Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Cdymax (India) Pharma is 29AAACI8027N1Z4, registered in Karnataka.
The CIN (Corporate Identification Number) of Cdymax (India) Pharma is U85110KA1994PTC016472. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Cdymax (India) Pharma has 11 court cases on record: 4 filed by the company and 7 filed against it. 3 are pending. Most are in the high courts.
Cdymax (India) Pharma was incorporated on 27 October 1994, making it 32+ years old. It is registered with the Registrar of Companies, Bangalore.
Cdymax (India) Pharma has 10 deals on record (6 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹66.48 Cr; the latest was in February 2020.
The peers of Cdymax (India) Pharma by revenue are Ajinomoto Bio-Pharma Services India Private Limited, Alembic Limited, Anjan Drug Private Limited, Arene Life Sciences (Unit 3) Private Limited, Vijayasri Organics Private Limited and 3 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Santosh Datta Naik ceased to be Additional Director on 29 Sep 2024. Santosh Datta Naik was appointed as Director on 08 Jan 2024. Rajeev Venkatesh Jahagirdar ceased to be Additional Director on 29 Sep 2021. Cdymax (India) Pharma has 9 board changes on record in total.
Cdymax (India) Pharma has 29 MSME Form 1 returns on record between 2018 and 2024, listing 1,058 overdue payments to 24 micro and small suppliers. The latest return was filed on 29 Apr 2024.
Cdymax (India) Pharma can be reached through the website cdymax.in. Its registered office is in Bangalore, Karnataka, India.